4D Molecular Therapeutics Inc

-0.06 (-0.22%)
Products, Regulatory

4D Molecular Therapeutics Presents Interim Results From Ongoing 4D-125 Phase 1/2 Clinical Trial

Published: 10/10/2021 19:59 GMT
4D Molecular Therapeutics Inc (FDMT) - 4d Molecular Therapeutics- Interim Results From Ongoing 4d-125 Phase 1/2 Clinical Trial in Patients With Advanced X-linked Retinitis Pigmentosa.
4d-125 Was Well Tolerated in All Patients Treated To-date.
4dmt Plans to Continue Enrollment at 1e12 Vg/eye in Dose Expansion Cohort, Including in Less Advanced Patients.
No Dose-limiting Toxicities Or Serious Adverse Events Were Observed.